What's in Zuyderland Medisch Centrum's pipeline?

Zuyderland Medisch Centrum has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Zuyderland Medisch Centrum's portfolio?

Top competitors by shared drug class: St. Antonius Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zuyderland-medisch-centrum.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Zuyderland Medisch Centrum — Portfolio Competitive Intelligence Brief

Zuyderland Medisch Centrum pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Artiss	Artiss	marketed			Other
Dabigatran + clopidogrel	Dabigatran + clopidogrel	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor	Cardiovascular
Dabigatran + Ticagrelor	Dabigatran + Ticagrelor	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor	Cardiovascular

Therapeutic area mix

Cardiovascular · 2
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

St. Antonius Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zuyderland Medisch Centrum:

Cite this brief

Drug Landscape (2026). Zuyderland Medisch Centrum — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zuyderland-medisch-centrum. Accessed 2026-05-16.